Your browser doesn't support javascript.
loading
Dasatinib: clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
Conchon, Monika; Freitas, Carla Maria Boquimpani de Moura; Rego, Maria Aparecida do Carmo; Braga Junior, José Wilson Ramos.
  • Conchon, Monika; Hospital Santa Marcelina. Hematology Service. São Paulo. BR
  • Freitas, Carla Maria Boquimpani de Moura; Instituto Estadual de Hematologia. Hospitalization Sector and Oncohematology Sector. Rio de Janeiro. BR
  • Rego, Maria Aparecida do Carmo; Bristol-Myers Squibb. Oncology Area. São Paulo. BR
  • Braga Junior, José Wilson Ramos; Bristol-Myers Squibb. Oncology Area. São Paulo. BR
Rev. bras. hematol. hemoter ; 33(2): 131-139, 2011. ilus, tab
Article in English | LILACS | ID: lil-596303
ABSTRACT
Dasatinib is a highly effective second generation tyrosine kinase inhibitor approved for the treatment of imatinib-resistant or intolerant chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. This article reviews the results of phase I, II and III studies and looks at the efficacy and safety of dasatinib. This review also provides practical recommendations for the management of side effects.
Subject(s)

Fulltext
Print
XML
Search on Google

Full text: Available Index: LILACS (Americas) Main subject: Piperazines / Drug Resistance / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Interferon-alpha / Gastrointestinal Tract / Protein Kinase Inhibitors / Drug-Related Side Effects and Adverse Reactions Type of study: Practice guideline Limits: Humans Language: English Journal: Rev. bras. hematol. hemoter Journal subject: Hematology Year: 2011 Type: Article Affiliation country: Brazil Institution/Affiliation country: Bristol-Myers Squibb/BR / Hospital Santa Marcelina/BR / Instituto Estadual de Hematologia/BR

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
Search on Google

Full text: Available Index: LILACS (Americas) Main subject: Piperazines / Drug Resistance / Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Interferon-alpha / Gastrointestinal Tract / Protein Kinase Inhibitors / Drug-Related Side Effects and Adverse Reactions Type of study: Practice guideline Limits: Humans Language: English Journal: Rev. bras. hematol. hemoter Journal subject: Hematology Year: 2011 Type: Article Affiliation country: Brazil Institution/Affiliation country: Bristol-Myers Squibb/BR / Hospital Santa Marcelina/BR / Instituto Estadual de Hematologia/BR